SURMOUNT-OSA · 2024

SURMOUNT-OSA — Tirzepatide for sleep apnea

Tirzepatide in adults with obesity and moderate-severe OSA.

Headline finding

Up to 62.8% reduction in apnea-hypopnea index.

Population
469 adults
Duration
52 weeks
Citation
Malhotra A et al., NEJM 2024

Summary is editorial; consult the original publication for the full methodology and statistical detail.

Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation